Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03989206 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
A Phase 3 study of Moderate-to-Severe Atopic Dermatitis, sponsored by Galderma R&D.
- Active
- Registry status
- Phase 3
- Development phase
- 1,700
- Enrollment target
- 20
- Study locations
NCT03989206: Active Phase 3 study of Moderate-to-Severe Atopic Dermatitis, sponsored by Galderma R&D.
NCT03989206 is a Phase 3 study of Moderate-to-Severe Atopic Dermatitis that is active but no longer recruiting, run by Galderma R&D. The registered enrollment target is 1,700 participants, above the 243-participant average among 4 other Moderate-to-Severe Atopic Dermatitis trials with a reported enrollment target (600% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03989206, a Phase 3 study of Moderate-to-Severe Atopic Dermatitis, is active but no longer recruiting, sponsored by Galderma R&D.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,700 participants
- Enrollment target
- 20
- Study locations
Study Summary
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Conditions Studied
Interventions
- DRUG Nemolizumab
Study Locations (20)
California
- Galderma Investigational Site 8831 - Anaheim
- Galderma Investigational Site 8906 - Bell Gardens
- Galderma Investigational Site 8456 - Beverly Hills
- Galderma Investigational Site 8578 - Cerritos
- Galderma Investigational Site 8577 - Encinitas
- Galderma Investigational Site 8636 - Fountain Valley
- Galderma Investigational Site 8224 - Fremont
- Galderma Investigational Site 8791 - Fresno
- Galderma Investigational Site 8888 - Fullerton
- Galderma Investigational Site 8845 - Huntington Beach
- Galderma Investigational Site 8833 - Inglewood
- Galderma Investigational Site 8686 - Lomita
- Galderma Investigational Site 8674 - Los Angeles
Alabama
- Galderma Investigational Site 8749 - Birmingham
- Galderma Investigational Site 8893 - Birmingham
- Galderma Investigational Site 8866 - Guntersville
Arizona
- Galderma Investigational Site 8808 - Scottsdale
- Galderma Investigational Site 8873 - Scottsdale
Arkansas
- Galderma Investigational Site 8447 - Fort Smith
- Galderma Investigational Site 8880 - North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,700 participants |
| Start Date | 2019-12-30 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 3 |
What the registry record for NCT03989206 still lists
NCT03989206 is an interventional study that assigns participants to a tested intervention. Its 1,700 participants enrollment target places it among the larger protocols in the corpus, above the 243-participant average among 4 other Moderate-to-Severe Atopic Dermatitis trials with a reported enrollment target (600% higher).
The record links to 1 condition, with Moderate-to-Severe Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Nemolizumab is the first listed.
NCT03989206 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT03989206 about?
NCT03989206 is a clinical study titled "Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis". Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
What is the current status of trial NCT03989206?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,700 participants. The study started on 2019-12-30. Estimated completion is 2026-08-31.
What conditions does trial NCT03989206 study?
This clinical trial studies the following conditions: Moderate-to-Severe Atopic Dermatitis.
What interventions are being tested in trial NCT03989206?
The interventions under investigation include: Nemolizumab (DRUG).
Who is sponsoring clinical trial NCT03989206?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03989206 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate-to-Severe Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
COMPLETED · Phase 3
-
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
COMPLETED · Phase 3
-
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 2
-
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI